Genitourinary Infections in Diabetes: Understanding Risk and Guiding the Diabetes Care Team

Abstract

Get full access to this article

View all access options for this article.

References

Gena

Bitew

Chane

, et al. Bacterial profile and antimicrobial susceptibility pattern of urinary tract infection among diabetic patients at Bule Hora University Teaching Hospital, Southern Ethiopia. Scientific Reports. 2025;15(1):24112. doi:10.1038/s41598-025-05782-8

Stapleton

Urinary tract infections in patients with diabetes. Am J Med. 2002;113(suppl 1A):80S-84S. doi:10.1016/s0002-9343(02)01062-8

Joshi

Caputo

Weitekamp

Karchmer

AW.

Infections in patients with diabetes mellitus. N Engl J Med. 1999;341(25):1906-1912. doi:10.1056/NEJM199912163412507

Sorescu

Cosnita

Braha

, et al. Predictive factors for urinary tract infections in patients with type 2 diabetes. J Clin Med. 2024;13(24):7628. doi:10.3390/jcm13247628

Paudel

John

Poorbaghi

Randis

Kulkarni

Systematic review of literature examining bacterial urinary tract infections in diabetes. J Diabetes Res. 2022;2022:3588297. doi:10.1155/2022/3588297

Chen

Jackson

Boyko

EJ.

Diabetes mellitus and urinary tract infection: epidemiology, pathogenesis and proposed studies in animal models. J Urol. 2009;182(6, suppl):S51-S56. doi:10.1016/j.juro.2009.07.090

Mohanty

Kamolvit

Scheffschick

, et al. Diabetes downregulates the antimicrobial peptide psoriasin and increases E. coli burden in the urinary bladder. Nat Commun. 2022;13(1):4983. doi:10.1038/s41467-022-32636-y

Pishdad

Auwaerter

Kalyani

RR.

Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review. Curr Diab Rep. 2024;24(5):108-117. doi:10.1007/s11892-024-01537-3

Rizzi

Trevisan

Genitourinary infections in diabetic patients in the new era of diabetes therapy with sodium-glucose cotransporter-2 inhibitors. Nutr Metab Cardiovasc Dis. 2016;26(11):963-970. doi:10.1016/j.numecd.2016.07.006

10.

Geerlings

Fonseca

Castro-Diaz

List

Parikh

Genital and urinary tract infections in diabetes: impact of pharmacologically induced glucosuria. Diabetes Res Clin Pract. 2014;103(3):373-381. doi:10.1016/j.diabres.2013.12.052

11.

Lupsa

Inzucchi

SE.

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118-2125. doi:10.1007/s00125-018-4663-6

12.

Confederat

Dragostin

Condurache

MI.

SGLT2 inhibitors and the risk of urogenital infections: a concise review. J Clin Med. 2025;14(6):1960. doi:10.3390/jcm14061960

13.

Kamei

Yamamoto

Complicated urinary tract infections with diabetes mellitus. J Infect Chemother. 2021;27(8):1131-1136. doi:10.1016/j.jiac.2021.05.012

14.

Njomnang Soh

Vidal

Huyghe

, et al. Urinary and genital infections in patients with diabetes: how to diagnose and how to treat. Diabetes Metab. 2016;42(1):16-24. doi:10.1016/j.diabet.2015.07.002

15.

Rangaswami

Bhalla

de Boer

, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020;142(17):e265-e286. doi:10.1161/CIR.0000000000000920

16.

Davies

Aroda

Collins

, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the ADA and EASD. Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034

17.

Yoosuf

, S DP, et al. Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: a meta-analysis. Endocrine. 2025;10.1007/s12020-025-04393-7. doi:10.1007/s12020-025-04393-7

18.

Benjamin

Schumacher

Characterization of risk factors for genitourinary infections with sodium-glucose cotransporter-2 inhibitors. Pharmacotherapy. 2020;40(10):1002-1011. doi:10.1002/phar.2458

19.

Burke

Conlin

Giles

, et al. Management of Type 2 Diabetes Mellitus. Department of Veterans Affairs; 2023.